High LDL is a question. Not automatically a diagnosis. And certainly not automatically a pill.
Why people in their 30s, athletes, and lifestyle-aware patients are prescribed statins almost daily in family-medicine practices, even though the indication often is not there. And what should come first.
Last week a 34-year-old sat in front of me. Slim. Athletic. She eats a balanced diet, very few processed foods. Non-smoker. Lab from her GP: LDL 165, Lp(a) elevated. Recommendation: statin, lifelong. Without a single further word. Without a single further test. Without a single image of her vessels. She asked me whether that was normal. And I said: unfortunately yes, it happens again and again. But that does not make it right.
A few weeks ago I wrote a long article about the cholesterol myth. About why cholesterol is not the perpetrator. Why it is the repair crew that tries to undo what sugar, stress, industrial seed oils and toxins have done to your endothelium.
This article is the necessary continuation. Because many readers wrote afterwards: "All well and good. But my GP still prescribed me a statin. Should I take it?"
The answer is not yes. The answer is not no. The answer begins with the question that was never asked.
You are in your mid-30s. Athletic. LDL a bit elevated. Statin. End of conversation.
I know this pattern very well. It is always the same story, with a different face.
She was 34, had a calm pulse and a finished statin prescription in her hand
Context. 34 years old. Architect. Two kids. Sport three times per week. Slim, BMI 21. Barely drinks, doesn't smoke. She eats a balanced diet, cooks for herself, very few ready-made foods. She comes to me because she had the feeling that something at her GP's went too fast.
The problem. Her GP had ordered a standard lipid panel. LDL: 165 mg/dl. Lp(a): elevated, around 95 mg/dl. The appointment lasted seven minutes. Recommendation: atorvastatin 20 mg. Lifelong. No discussion of lifestyle. No discussion of risk profile. No hsCRP. No Apo-B. No HOMA-IR. No CAC score. No fasting insulin. She was simply supposed to take the pill.
The finding. We then did what did not happen at the GP. Apo-B was moderately elevated, triglycerides low, HDL high, HOMA-IR optimal, hsCRP under one, omega-3 index good. Lp(a) was indeed elevated. We did a coronary calcium score. Score: zero. Completely clean vessels.
The turning point. I told her: statins do not lower Lp(a). They can even raise it slightly. And a calcium score of zero in a 34-year-old with a good metabolic profile is the exact opposite of an emergency. It is an invitation to work on the endothelium in a targeted way, not to reflexively switch on pharmacology.
The result. She did not start the statin. She drastically reduced her linoleic acid intake, sleeps more since then, walks fasted in the morning. We follow her values. I cannot claim causality, but I document the temporal association. Apo-B slightly down, energy noticeably better. Plaque will be monitored over the coming years.
The lesson. Prescribing a pill before anyone has looked at the vessels is medically the equivalent of writing a fire-safety concept without doing a fire inspection.
To be clear up front: I am not generally against statins. In the right people, in the right constellation, they are very likely useful. More on that below. But exactly this kind of differentiation simply does not happen in many GP practices.
A high LDL is not a finding. It is a question. The answer to it depends on ten other values and a single piece of imaging. Anyone who hands you a lifelong medication after three values and seven minutes has not asked the question.
And now you know why this article needs to exist.
Atorvastatin was the highest-grossing medication on the planet from 1996 to 2012. To this day. Cumulatively.
Before we talk about indications, I want to give you context that does not appear in any patient information leaflet. Statins are not just any medication. They are the pharmaceutical phenomenon of the past 30 years.
Market dataLipitor (atorvastatin) as a financial phenomenon
Lipitor was launched in 1996 by Pfizer. By the time the patent expired in 2011, this single statin had sold for about 125 billion US dollars. By the end of 2022, cumulative sales reached around 172 billion US dollars. In peak years Lipitor generated more than 12 billion dollars in annual revenue and accounted for roughly a quarter of Pfizer's total turnover.
It is the highest-grossing prescription drug in pharmaceutical history. Just to be clear: that something sells well does not automatically make it wrong. But it shows the marketing budget, the rep density and the textbook penetration with which an entire generation of family physicians was trained and continuously updated.
Pfizer. Lipitor (atorvastatin), business data and market analysis 1996-2022. Statista, 2023. statista.com; see also Garrett T, "Weekly Dose: Lipitor", The Conversation, 2017. theconversation.com
I am not telling you this to feed conspiracy theories. I am telling you this so that you understand why the reflexive prescription is so well established in many practices. On top of that comes the everyday reality of primary-care medicine: on average seven to ten minutes per patient, high bureaucratic load, quarterly budgets. Anyone who sees a lipid profile in that time and has to act fast reaches for the most-researched, most system-supported solution.
What the German guidelines actually say
This is where it gets interesting. Many patients think the German guidelines instructed their GP to prescribe a statin straight away. That is not the case.
NVL Chronic CHD 2024 and DEGAM-S3 Primary-care Cardiovascular Risk Counselling
The German National Disease Management Guideline for Chronic Coronary Heart Disease, version 7 (2024), does not address primary prevention of CHD. For that question it refers to the DEGAM S3 guideline, "Primary-care Risk Counselling for Cardiovascular Prevention".
The DEGAM guideline in turn emphasises shared decision making based on absolute ten-year risk. A single elevated LDL value, without consideration of age, sex, blood pressure, smoking status, diabetes, family history and lifestyle, is explicitly not sufficient grounds for a statin prescription in primary prevention. The recommendation is to clarify individual treatment preferences together with the patient.
In plain English: anyone who prescribes you a statin after three cholesterol values and without a conversation about lifestyle is not necessarily acting in line with the guidelines.
German Medical Association (BÄK), National Association of Statutory Health Insurance Physicians (KBV), AWMF. Nationale VersorgungsLeitlinie Chronische KHK, Version 7, 2024. AWMF reg. no. nvl-004. register.awmf.org/nvl-004; DEGAM. S3-Leitlinie Hausärztliche Risikoberatung zur kardiovaskulären Prävention, reg. no. 053-024, 2018.
I am not writing this to attack colleagues. Many family physicians do an excellent job. I know enough of them who provide exactly this kind of differentiated counselling, in twelve-hour days, against the current. But a not insignificant number works differently. Reflexively, with a pill as the answer instead of a question. This article is for exactly that subset.
If your GP writes a lifelong prescription after three values and seven minutes, that is not "the guideline". It is an abbreviation of the guideline. You have the right to the full discussion.
And now you know why the pill so easily ends up in the patient's hand without the question being asked.
Cholesterol is the painter. Not the one who broke the wall.
If you have read the cholesterol-myth article, you can skim this section. If not, here is the essence in three paragraphs.
Cholesterol builds your cell membranes, your steroid hormones, your bile acids, your vitamin-D precursor. About 75 to 80 per cent of it is made by your liver itself, completely independent of how many eggs you eat. Anyone who lowers cholesterol across the board without knowing why it is high is treating a sensor, not a problem.
LDL is not just LDL. There is a phenotype A: large, fluffy, hardly atherogenic. There is a phenotype B: small, dense, oxidation-prone, strongly atherogenic. What drives phenotype B is not butter. It is sugar, insulin resistance, stress and industrial seed oils.
LDL ends up in plaque because the plaque is a repair. The actual damage is done by hyperglycaemia, oxidised linoleic acid, stress, heavy metals, mycotoxins, sleep deprivation and sedentary living. Those are the irritants attacking the endothelium. Cholesterol tries to close the cracks.
Statins block a single enzyme. What they take with them rarely makes it onto the package insert.
Statins inhibit an enzyme in your liver called HMG-CoA reductase. That enzyme is the bottleneck of cholesterol synthesis. Block it, hepatic cholesterol production goes down, the liver pulls more LDL out of the blood, the value drops. So far, so functional.
What is rarely discussed: the same metabolic pathway that produces cholesterol also produces other molecules. If you turn off the tap upstream, several things go missing downstream simultaneously.
What is also inhibited when HMG-CoA reductase is blocked
- Coenzyme Q10 (ubiquinone). Essential for the respiratory chain in your mitochondria. Less CoQ10, less ATP. Fatigue, exercise intolerance and muscle pain become plausible.
- Dolichol. Important for protein glycosylation, the system that makes sure proteins find their address inside your cells.
- Vitamin K2 (menaquinone). Steers calcium out of the arteries and into the bones. Reducing it is the opposite of what statins are supposed to achieve.
- Selenoproteins. Including glutathione peroxidase, one of your central antioxidant shields against oxidative stress.
- Steroid hormone precursors. Cholesterol is the mother of testosterone, oestrogen, progesterone, cortisol. Statins lower testosterone slightly on average, in a statistically significant way.
Mechanism reviewOkuyama et al., 2015. Statins as mitochondrial and vascular off-target compounds
The authors compiled mechanistically in this review in Expert Review of Clinical Pharmacology why statins could cause more harm than benefit in some people. They argue that the paradoxical increase in heart failure and arterial calcification despite LDL lowering may be partly mediated by exactly these off-target effects.
Important: this is a hypothesis, not a definitive proof. But it is pharmacologically plausible and is almost never raised in routine prescribing.
Okuyama H, Langsjoen PH, Hamazaki T, et al. Statins Stimulate Atherosclerosis and Heart Failure: Pharmacological Mechanisms. Expert Rev Clin Pharmacol. 2015;8(2):189-199. doi.org/10.1586/17512433.2015.1011125
Schooling et al., 2013. Statins lower testosterone slightly but significantly
This meta-analysis pooled placebo-controlled trials that measured testosterone under statin therapy. Testosterone fell on average by about 0.44 nmol/l. The effect was somewhat larger in men, but it was also detectable in women with PCOS.
The clinical relevance of this small shift is debated. In a 25-year-old with already borderline testosterone, however, it could noticeably affect sleep, mood, libido and training progress. In a 65-year-old with clear cardiovascular damage, it is secondary.
Schooling CM, Au Yeung SL, Freeman G, et al. The effect of statins on testosterone in men and women. BMC Med. 2013;11:57. doi.org/10.1186/1741-7015-11-57
Statins do not only lower cholesterol. With the same lever they reach into energy production, hormones, the antioxidant system and the calcium handling of your arteries. In a 34-year-old athlete this off-target load weighs differently than in a 70-year-old with a stenotic coronary artery.
When statins really help. And when they are a step too soon.
So nobody misunderstands me: there are clear constellations in which statins very likely extend life. And there are constellations in which they barely change anything but do produce side effects.
So there is no "statin good" or "statin bad". There is only "statin in which situation, with which goal, with which alternative tested, with which follow-up tracked".
Cai et al., 2021, BMJ. Statins in primary prevention, benefits and harms
This very large review found real but modest benefits in primary prevention. At the same time it showed an increased risk for muscle complaints, liver dysfunction, kidney impairment and eye problems. The question is not "statin yes or no" but how absolute benefits and absolute harms add up for your specific risk profile.
Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease. BMJ. 2021;374:n1537. doi.org/10.1136/bmj.n1537
Cohort analysis, 5 guidelinesMortensen et al., 2019, JAMA Cardiology. NNT depending on baseline risk
This analysis used the Copenhagen General Population Study to compare the recommendations of the five major guidelines. The central message in one number: for low-risk individuals the Number Needed to Treat is around 400 to prevent a single cardiovascular event over five years. For high-risk patients it is around 25.
That is to say: for a young, healthy person with isolated high LDL, 400 people take a statin for five years so that a single one of them is spared an event. The other 399 take a pill without benefiting from it but very much carrying its side-effect risk.
Mortensen MB, Nordestgaard BG. Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat. JAMA Cardiol. 2019;4(11):1131-1138. doi.org/10.1001/jamacardio.2019.3665
For young, healthy people with isolated high LDL the Number Needed to Treat is often beyond 200. That is not an indication. That is pharmacology on hope.
It is never a single value. It is always the whole system.
The probably most important study of modern cardiology on the question "how does a heart attack actually arise?" is not an LDL study. It is a study about what happens together.
Case-control, n=29,972, 52 countriesYusuf et al., 2004, Lancet. INTERHEART
Salim Yusuf and his international team studied nearly 30,000 people in 52 countries, of whom 15,152 with a first heart attack and 14,820 as controls. They asked: which modifiable factors together explain heart-attack risk?
The result moved the field. Nine factors explain over 90 per cent of cardiovascular risk worldwide, in both sexes and across all age groups.
Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study). Lancet. 2004;364(9438):937-952. doi.org/10.1016/S0140-6736(04)17018-9
What are these nine factors, weighted by their share of population risk?
The nine INTERHEART factors in descending order
- Apo-B/Apo-A1 ratio in the top quintile. Population Attributable Risk (PAR) about 49 per cent. Meaning: nearly half of all heart attacks are linked to this lipid ratio, not to isolated LDL.
- Smoking. Odds ratio 2.87. PAR around 36 per cent.
- Psychosocial factors. Stress, depression, financial worries. PAR around 33 per cent.
- Abdominal obesity (waist circumference). PAR around 20 per cent.
- Hypertension. PAR around 18 per cent.
- Low fruit and vegetable intake. PAR around 14 per cent.
- Physical inactivity. PAR around 12 per cent.
- Diabetes mellitus. PAR around 10 per cent.
- Light, regular alcohol consumption as a protective factor. To be interpreted with caution, methodologically weaker.
Important to see: what lipidology captures as a risk factor here is not pure LDL but the Apo-B/Apo-A1 ratio. In other words, the number of atherogenic particles relative to the number of protective ones. That is a fundamentally different statement from "high LDL is dangerous".
On top of that come factors that INTERHEART did not capture but that modern functional medicine documents well: chronic low-grade inflammation (measured by hsCRP), insulin resistance and its precursors, heavy-metal burden, mycotoxin exposure from contaminated indoor environments, oxidative stress from industrial seed oils, poor sleep and low HRV. They all irritate the endothelium.
Hypertension, insulin resistance, abdominal fat, stress, toxins, exercise, sleep, Apo-B ratio. That is your real risk map. A pill that touches only one point on this map cannot redraw the whole map.
High Lp(a) plus a statin? That does not solve the very problem it is supposed to solve.
This is the part that troubles me most. Lp(a), pronounced "lipoprotein little a", is a genetically determined particle whose level barely changes over a lifetime. Anyone with high Lp(a) has an increased risk of early heart attack and aortic-valve stenosis, independently of everything else. So far the evidence is robust.
What many GPs do not know or do not consider: statins do not lower Lp(a). They raise it slightly. The large subject-level meta-analysis by Tsimikas and colleagues in the European Heart Journal shows this very clearly.
Tsimikas et al., 2020, European Heart Journal. Statins increase Lp(a)
Sotirios Tsimikas and colleagues pooled six randomised placebo-controlled trials at the subject level. 5,256 patients, 1,371 in the placebo group and 3,885 in the statin group. Atorvastatin, pravastatin, rosuvastatin, pitavastatin in different doses.
Result: Lp(a) rose on average by 11 per cent under statin. In individual subgroups it rose by up to 19.6 per cent. Under placebo, Lp(a) fell slightly. The effect was statistically highly significant and reproduced in practically all subgroups.
Consequence for you: anyone who reflexively gets a statin because of high Lp(a) is not treating the namesake problem. In this indication statins are pharmacologically misaddressed.
Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275-2284. doi.org/10.1093/eurheartj/ehz310
What do we do instead with high Lp(a)? Currently there is no approved specific Lp(a)-lowering therapy in routine prescribing. There are promising antisense oligonucleotides in phase-3 trials, such as pelacarsen. They are not for everyday primary-care practice. What you can do: drive the rest of your overall risk down as far as possible. Optimise insulin sensitivity, care for the endothelium, lower inflammation, normalise blood pressure, monitor plaque with imaging.
High Lp(a) is not a "statin indicator". It is a cue that your overall risk profile must be examined very carefully. A pill that does not lower the namesake particle cannot be the answer to that particle.
Even if LDL as a class contributes causally, an LDL number without subclass differentiation says little about you.
I have to be fair here for a moment. There is very strong evidence, especially from Mendelian randomisation studies, that LDL as a class contributes causally to atherosclerosis. That is the position of the EAS consensus statement of 2017. It is real, it is solid, it does not vanish because I find it inconvenient.
But: the same research says that not every LDL is equally dangerous. There are at least two phenotypes.
LDL subclasses, simplified
- Phenotype A (large, fluffy LDL). Big, light, gives its cholesterol cleanly to cells. Hardly atherogenic. Rises with exercise, olive oil, saturated fats.
- Phenotype B (small, dense LDL). Small, dense, oxidation-prone, easily penetrates the arterial wall. Strongly atherogenic. Rises with sugar, insulin resistance, industrial seed oils, stress.
Two people can have the same LDL value and bring an entirely different risk to the table. What distinguishes them is the number of atherogenic particles. That is exactly what Apo-B measures. An LDL number alone does not.
Sniderman, 2013. Apo-B is superior to cholesterol markers
Allan Sniderman has shown in a large discordance analysis that Apo-B is superior to both non-HDL cholesterol and LDL cholesterol as a risk predictor. When Apo-B and LDL-C disagree, Apo-B is the better forecast. His point: "Epidemiology without consideration of physiology is like shooting without aiming."
Sniderman A, Kwiterovich PO. Update on the detection and treatment of atherogenic low-density lipoproteins. Curr Opin Endocrinol Diabetes Obes. 2013;20(2):140-147. doi.org/10.1097/MED.0b013e32835ed9cb
Consequence: lowering LDL at any cost is not necessarily "good". Anyone who lowers LDL by 30 per cent on a vegan diet but at the same time raises the sd-LDL fraction because more bread, more seed oils, more triglycerides are in play, may not have lowered the risk but merely shifted it. A standard lab panel simply does not show this.
What the data on plant-based versus animal-based actually says
This discussion is emotional, I am trying to stay sober. The following points are well documented.
Termannsen et al., 2022, Obes Rev. Plant-based diets and cardiovascular endpoints
This systematic review looked across multiple meta-analyses at what a vegetarian or vegan-dominated diet actually changes. It moderately lowers total cholesterol, LDL and blood pressure, and reduces, on observational data, the risk of ischaemic heart disease by about 25 per cent. For all-cause mortality, stroke and overall cardiovascular mortality the effect is small, mixed or non-significant.
Important: plant-based diets have so far not been tested in randomised trials with hard cardiovascular endpoints. The evidence for "vegan protects against heart attack" comes almost exclusively from observational data. Observational data correlates, it does not prove.
Termannsen AD, Clemmensen KKB, Thomsen JM, et al. Effects of vegan diets on cardiometabolic health: A systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2022;23(9):e13462. doi.org/10.1111/obr.13462
Put differently: that a vegan diet lowers LDL is well documented. That it prevents heart attacks is not documented to the same degree. That is an important distinction that is rarely made in consultation.
And what do I see in practice with low-carb and carnivore?
This is where it gets interesting, because the evidence contradicts the public picture.
RCT, n=40, 12 weeksVolek et al., 2009. Carbohydrate restriction lowers the atherogenic lipid profile
Jeff Volek and colleagues randomised 40 overweight people with metabolic syndrome to a 12-week RCT: low-carb versus low-fat. Both lost weight. But the atherogenic lipid profile improved markedly more under low-carb: triglycerides down, HDL up, LDL particle number down, sd-LDL fraction down, inflammatory markers down.
Two-year data from Athinarayanan also show that on a ketogenic diet in patients with type-2 diabetes, lipid subclasses improve, even though LDL-C in some cases rises.
Volek JS, Phinney SD, Forsythe CE, et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Lipids. 2009;44(4):297-309. doi.org/10.1007/s11745-008-3274-2
What I observe in practice in many patients matches the literature: in metabolically not-quite-healthy people, a carbohydrate-reduced or ketogenic-leaning diet very often lowers exactly the values that really matter. Triglycerides, sd-LDL fraction, hsCRP, insulin, HOMA-IR. In a subgroup of lean, athletic people, the so-called Lean-Mass Hyper-Responders, LDL-C can rise markedly under low-carb, but plaque does not grow in parallel. That is exactly what the KETO-CTA study 2025 showed.
A lowered LDL on a lab printout is not a proof of a longer life. A vegan lifestyle lowers LDL, but does not necessarily lower your risk. A low-carb diet can lower LDL in some, raise it slightly in others, while clearly improving the dangerous sd-LDL and triglycerides. The goal is not "LDL low". The goal is "endothelium intact, atherogenic particles few, inflammation low".
Most statin patients do not know that these effects could be related to the pill.
Statins are not a sweet. They are a potent pharmaceutical. In high-risk patients, the absolute benefit clearly outweighs everything. At lower risk, this balance shifts noticeably.
Muscle complaints
Statin-associated muscle symptoms (SAMS) in real-world care. Diffuse pain, weakness, exercise intolerance. Part of it is nocebo-mediated, part of it is real.
Diabetes risk
Increased risk for new-onset type 2 diabetes. One additional case of diabetes per 255 statin-years (Sattar 2010, Lancet).
CoQ10 reduction
Plasma CoQ10 can drop by about 40 per cent under a statin. Mitochondrial energy production may suffer noticeably, especially under exertion.
Testosterone
nmol/l mean reduction (Schooling 2013). In some men with already low T noticeable in energy, mood, libido.
Lp(a) increase
Average across studies, in subgroups up to 19.6 per cent (Tsimikas 2020). The exact opposite of what many prescriptions assume.
Cognitive effects
Diffuse brain fog, word-finding problems. Disputed in RCTs, reported in practice. On suspicion: pause, retest.
The SAMSON study (Howard 2021, JACC) showed that a substantial part of reported statin side effects also occurs under placebo tablets, so it is nocebo-mediated. That is important to know, but it does not change the fact that real off-target effects also exist. The question is not "real or nocebo" but "how much risk am I taking for how much absolute benefit".
The individual side effects, in mechanism and practice
So that you are not fobbed off with platitudes, I want to break down the most important possible side effects in more detail. That way, here you receive the kind of informed-consent discussion that systematically does not happen in a seven-minute GP appointment.
1. Muscle complaints and mitochondria
Statins lower not only cholesterol but also the body's own production of coenzyme Q10 and heme A. Both are essential for ATP production in your mitochondria. Plasma CoQ10 can drop by up to 40 per cent under a statin. That is not nothing. Anyone who trains, exercises regularly, or already has a borderline energy reserve, may notice it: heavy legs, worse recovery, exercise intolerance. In severe cases, very rare but real, an immune-mediated necrotising myopathy can occur, which is HMG-CoA-reductase-antibody positive and continues after withdrawal. More common are diffuse muscle complaints, called SAMS in clinical care, with frequencies between 10 and 25 per cent in real-world cohorts.
2. Diabetes risk
The Sattar meta-analysis (Lancet 2010) shows about 9 per cent increased risk for new-onset type 2 diabetes under statin therapy. These 9 per cent are a relative risk; in absolute numbers, one additional case of diabetes occurs per 255 statin-years. That sounds small. It is small if your cardiovascular risk is high and you are trading protection from a heart attack for a moderate diabetes risk. In a slim, otherwise healthy person with isolated high LDL and low absolute risk, that balance shifts noticeably. The mechanism is not fully understood; effects on insulin secretion and insulin sensitivity, as well as impaired GLUT-4 translocation in muscle cells, are discussed.
3. Hormone system and testosterone
Cholesterol is the mother of all steroid hormones. If you turn off the tap upstream, material is missing downstream. The Schooling meta-analysis (BMC Med 2013) shows a mean testosterone reduction of 0.44 nmol/l. That sounds small. In a 30-year-old with an already borderline value, however, it can become noticeable in sleep, mood, libido, training progress and bone health. In a 65-year-old with clear plaque it is secondary. Exactly this differentiation belongs in the informed-consent conversation.
4. Vitamin K2 and arterial calcification
This is where it gets paradoxical. Statins also inhibit, via the mevalonate pathway, the synthesis of vitamin K2 (menaquinone). Vitamin K2 is the vitamin that pulls calcium out of the arteries and into the bones. A reduction of vitamin K2 could lead to more arterial calcification, which is exactly what statins are supposed to prevent. This is a hypothesis, not a definitive proof. But it fits the finding from some observational studies that coronary calcification under statins tends to progress faster, even though plaque stability improves. The interpretation is debated, the question is open.
5. Antioxidant defence and oxidative stress
Selenoproteins like glutathione peroxidase use the same mevalonate pathway as cholesterol. If statins are given, this protective shield can suffer too. In young people who are already in an oxidatively burdened lifestyle (stress, lots of screen time, mediocre sleep), this is relevant.
6. Cognitive symptoms
Diffuse brain fog, word-finding problems, slower thinking. Inconsistent in RCTs, broadly documented in practice and patient reports. The FDA added this hint to the package insert in 2012. Anyone who notices this should speak with the prescribing doctor, pause the statin and re-evaluate under medical supervision.
7. Liver and kidney values
Elevations of transaminases (ALT, AST) occur in a low single-digit percentage, are usually mild and reversible. Kidney impairment and eye problems were named as additional risks in the Cai meta-analysis 2021. That belongs in regular monitoring.
8. Lp(a) increase
Already covered in detail in step 7. On average +11 per cent under statin (Tsimikas 2020). If your indication is explicitly based on high Lp(a), this is an off-target effect with a sign reversal.
This list is not an argument against statins. It is an argument for an informed-consent conversation. If your absolute risk is high, the benefit clearly outweighs these risks. If your absolute risk is low, these risks are the other side of the coin. Exactly this weighing is the medical task that cannot be done in seven minutes.
And now you know why the question is not whether statins have side effects. The question is whether your indication justifies these side effects.
Before anyone says "statin", these steps belong in the conversation.
Imagine going to an architect and saying: "I think my house is unstable." He answers: "Let's tear out the load-bearing wall and rebuild it." Before he has seen the foundation. Before he has measured the cracks. Before he knows whether it even is a load-bearing wall. You would not hire him.
But this is exactly the order that happens in many GP practices. High LDL, then pill. Lp(a) elevated, then pill. Triglycerides high, then pill. Before the foundation has been examined.
Prospective cohortGreenland et al., 2018. Calcium score as the decisive risk differentiator
The MESA study and follow-on analyses show that a calcium score of zero in someone with statistically "moderate" risk often shifts the true probability of a cardiovascular event in the next ten years to under two per cent. Conversely, a high score moves a "low" estimate into the high-risk territory.
Consequence: the CAC score can take statin candidates out of the recommendation, or bring them into it, much more precisely than any risk formula on its own. When the indication is unclear, it belongs in the diagnostics.
Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary Calcium Score and Cardiovascular Risk. J Am Coll Cardiol. 2018;72(4):434-447. doi.org/10.1016/j.jacc.2018.05.027
A differentiated lipid panel plus a calcium score together cost less than a year of statin therapy, and they can free you from a lifelong medication you may never have needed. That is medicine that asks before it treats.
Before the pill comes what the pill is actually trying to imitate.
Statins lower cholesterol. But that is not the goal. The goal is an intact endothelium. And that is exactly what you can support, in many cases, with targeted lifestyle levers far better than any pill can.
What true endothelial care really means
- Industrial seed oils out. Sunflower, safflower, soy, corn, canola. They deliver linoleic acid that oxidises in your body and shifts LDL from phenotype A to phenotype B.
- Optimise insulin sensitivity. Fast carbs out, especially after 6 pm. Movement throughout the day. HbA1c towards 5.0 per cent. Triglyceride-to-HDL ratio under 1.5.
- Sleep between 10 pm and 6 am. Deep sleep in the first half of the night regenerates endothelium and HRV. Little sleep, poor HRV, stressed endothelium.
- Stress hygiene in the evening. HPA calming. Breathing exercise, walk, no doomscrolling. Cortisol down, cholesterol synthesis settles, endothelium breathes.
- Raise the omega-3 index. Wild fish, algae oil. Reduces lipid peroxidation and influences platelet aggregation favourably.
- Close micronutrient gaps. Vitamin D, B12, folate, magnesium, selenium. They are the tools your endothelium repairs itself with.
- Movement as endothelial medicine. NO production in the vessels responds very directly to movement. Brisk walking three to five times per week is not symbolic, it is pharmacology.
If you pull these levers consistently over three to six months and follow the right values, the need for pharmacology will look different, in many people, than after a seven-minute GP appointment. For some, the indication for a statin remains, but then it is justified, not reflexive.
You are not a value on a slip of paper. You are a system.
The question that bothers me most about all of this is not medical. It is human. It goes: What do we do to people when we tell them at 30 that they have a chronic risk and need to take a medication for life?
We disconnect them from the experience that their body responds to lifestyle. We train out of them the awareness that sleep, diet, exercise, stress are real tools with which they can influence their physiology. We turn them into patients before they are really sick.
That is not small. That is an identity-changing statement about a young person.
Three things you can do this week if your GP reflexively prescribed you a statin.
First, ask for the numbers that really count. Apo-B. Lp(a) once. HOMA-IR or fasting insulin. hsCRP. HbA1c. Triglyceride-to-HDL ratio. If your GP does not know these values or does not consider them relevant, that is a hint that the cholesterol discussion in this practice has not been updated.
Second, ask for imaging. A CAC score by low-dose CT between 35 and 70 is one of the most powerful diagnostic tools in modern cardiology. It answers the question whether your risk is an estimate or a real finding. Statutory health insurance does not always cover it, sometimes it does. It costs between 100 and 200 euros and can re-evaluate a lifelong medication recommendation.
Third, focus on insulin sensitivity and linoleic acid. Look in your cupboard. Throw out the industrial seed oils. Replace them with extra-virgin olive oil, butter, ghee. Eat protein- and vegetable-heavy, reduce fast carbs, walk for ten minutes after meals. Three to six months consistently. Then have the values measured again. Very often the profile then looks markedly different.
If you want not only to read but to truly understand whether a statin is really indicated for you, you can book an appointment below this article. We will then walk through your values together. With the differentiated view this topic deserves.
Sources
Statins: indication, benefit, Number Needed to Treat
Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease. BMJ. 2021;374:n1537. doi.org/10.1136/bmj.n1537
Mortensen MB, Nordestgaard BG. Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat. JAMA Cardiol. 2019;4(11):1131-1138. doi.org/10.1001/jamacardio.2019.3665
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742. doi.org/10.1016/S0140-6736(09)61965-6
Mechanism, off-target and hormonal effects
Okuyama H, Langsjoen PH, Hamazaki T, et al. Statins Stimulate Atherosclerosis and Heart Failure: Pharmacological Mechanisms. Expert Rev Clin Pharmacol. 2015;8(2):189-199. doi.org/10.1586/17512433.2015.1011125
Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women. BMC Med. 2013;11:57. doi.org/10.1186/1741-7015-11-57
Howard JP, Wood FA, Finegold JA, et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. J Am Coll Cardiol. 2021;78(12):1210-1222. doi.org/10.1016/j.jacc.2021.07.022
Lp(a) and statin therapy
Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275-2284. doi.org/10.1093/eurheartj/ehz310
Kamstrup PR. Lipoprotein(a) and Cardiovascular Disease. Clin Chem. 2021;67(1):154-166. doi.org/10.1093/clinchem/hvaa247
Diagnostics and imaging
Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary Calcium Score and Cardiovascular Risk. J Am Coll Cardiol. 2018;72(4):434-447. doi.org/10.1016/j.jacc.2018.05.027
Sniderman A, Kwiterovich PO. Update on the detection and treatment of atherogenic low-density lipoproteins. Curr Opin Endocrinol Diabetes Obes. 2013;20(2):140-147. doi.org/10.1097/MED.0b013e32835ed9cb
Multifactorial cardiovascular risk
Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study). Lancet. 2004;364(9438):937-952. doi.org/10.1016/S0140-6736(04)17018-9
Dietary influences on lipids and risk
Termannsen AD, Clemmensen KKB, Thomsen JM, et al. Effects of vegan diets on cardiometabolic health. Obes Rev. 2022;23(9):e13462. doi.org/10.1111/obr.13462
Volek JS, Phinney SD, Forsythe CE, et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Lipids. 2009;44(4):297-309. doi.org/10.1007/s11745-008-3274-2
Soto-Mota A, Norwitz NG, Manubolu VS, et al. Longitudinal Data From the KETO-CTA Study. JACC Adv. 2025;4(7):101686. doi.org/10.1016/j.jacadv.2025.101686
Dinu M, Abbate R, Gensini GF, Casini A, Sofi F. Vegetarian, vegan diets and multiple health outcomes. Crit Rev Food Sci Nutr. 2017;57(17):3640-3649. doi.org/10.1080/10408398.2016.1138447
German guidelines
German Medical Association (BÄK), National Association of Statutory Health Insurance Physicians (KBV), AWMF. National Disease Management Guideline Chronic Coronary Heart Disease, Version 7. AWMF reg. no. nvl-004, 2024. register.awmf.org/de/leitlinien/detail/nvl-004
German Society of General Practice and Family Medicine (DEGAM). S3 Guideline Primary-care Risk Counselling for Cardiovascular Prevention. AWMF reg. no. 053-024, 2018.
Market data atorvastatin (Lipitor)
Statista. Pfizer Lipitor (atorvastatin) global revenues 2003-2019 and cumulative lifetime sales through 2022. statista.com
Garrett TJ. Weekly Dose: Lipitor, the highest-selling drug of all time. The Conversation. 2017. theconversation.com
Background cholesterol and endothelium
DiNicolantonio JJ, O'Keefe JH. Omega-6 vegetable oils as a driver of coronary heart disease: the oxidized linoleic acid hypothesis. Open Heart. 2018;5(2):e000898. doi.org/10.1136/openhrt-2018-000898
Vekic J, Zeljkovic A, Cicero AFG, et al. Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL. Medicina (Kaunas). 2022;58(2):299. doi.org/10.3390/medicina58020299
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188. doi.org/10.1093/eurheartj/ehz455